Ponatinib Extends Survival Over Transplant in Chronic Phase CML: The results of a new study that included patients from the PACE trial and the European Bone Marrow Transplant registry revealed that treatment with ponatinib yielded better overall survival (OS) compared
with allogeneic stem cell transplantation (allo - SCT) in patients with chronic phase chronic myeloid leukemia (CP - CML) with a T315I mutation.
Not exact matches
In the study, analysis of patient samples demonstrated that high LSC17 scores meant poor outcomes
with current standard treatment, even for patients who had undergone
allogeneic stem cell transplantation.
In that program, we focused on treating children
with both malignant and genetic conditions
with generally
allogeneic hematopoietic
stem cell transplantation.
The only documented long - term complete remissions reported in multiple myeloma patients have occurred
with allogeneic bone marrow
transplantation, where a donor's blood
stem cells (graft) are transplanted into the patient (host)
with multiple myeloma.
Allogeneic Sibling Donor Peripheral Blood
Stem Cells Transplantation With Myeloablative Conditioning for Chronic Myeloid Leukemia in Blast Crisis - Successful Treatment Despite Severe Phase of the Disease
Horwitz et al 79 reported that donor MSC contributed to bone remodelling after
allogeneic stem cell transplantation (SCT) in 3 children
with osteogenesis imperfecta, a rare genetic disorder of type I collagen.
In the future, outpatient blood and bone marrow
stem cell transplantation will be offered to a broader group of patients
with other blood disorders and for
allogeneic transplants (transplant from non-twin donor
stem cells).
Use of a lower dose of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose in children
with hematologic malignancies undergoing
allogeneic hematopoietic
stem cell transplantation (HSCT) from an unrelated donor, according to the results of a study published in Lancet Oncology.
Low - Dose ATLG Prevents GVHD in Pediatric Hematologic Malignancies: A newly published randomized phase III study of pediatric patients showed lower doses of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose in children
with hematologic malignancies undergoing
allogeneic hematopoietic
stem cell transplantation from an unrelated donor.
Acute myeloid leukemia (AML) is the leading cause of leukemia mortality in the United States.1 Curative treatment involves intensive induction chemotherapy, before proceeding to either consolidation chemotherapy or
allogeneic stem cell transplantation based on the patient's risk for relapse.2 This approach has been employed for > 4 decades and, although most individuals achieve complete remissions
with front - line therapy, 3 the majority of patients ultimately relapse
with drug - resistant disease, and overall survival rates remain disappointingly poor.4 The limited ability of many patients to tolerate the intense chemotherapy - based treatments, in particular hematological toxicity, further contributes to the poor outcomes noted in this disease.
Macmillan, 2014; Holler, E., et al. «Metagenomic analysis of the stool microbiome in patients receiving
allogeneic stem cell transplantation: Loss of diversity is associated
with use of systemic antibiotics and more pronounced in gastrointestinal graft - versus - host disease.»